pazopanib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiogenesis inhibitors 4118 444731-52-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • GW786034B
  • pazopanib
  • votrient
  • GW 786034
  • pazopanib hydrochloride
  • pazopanib HCl
Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumor xenografts in mice.
  • Molecular weight: 437.52
  • Formula: C21H23N7O2S
  • CLOGP: 3.50
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 119.03
  • ALOGS: -4
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.06 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 14, 2010 EMA
Oct. 19, 2009 FDA NOVARTIS PHARMS CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 589.81 21.55 302 11815 64624 46609321
Hair colour changes 384.68 21.55 90 12027 1702 46672243
Death 293.29 21.55 395 11722 335153 46338792
Diarrhoea 293.09 21.55 519 11598 559083 46114862
Hypertension 223.10 21.55 264 11853 196092 46477853
Disease progression 120.62 21.55 133 11984 91167 46582778
Fatigue 111.79 21.55 378 11739 608319 46065626
Nausea 110.11 21.55 408 11709 687046 45986899
Decreased appetite 109.60 21.55 187 11930 193649 46480296
Product use in unapproved indication 108.15 21.55 125 11992 90148 46583797
Soft tissue sarcoma 99.79 21.55 18 12099 82 46673863
Renal cell carcinoma 89.76 21.55 34 12083 3504 46670441
Hepatic function abnormal 83.19 21.55 70 12047 34351 46639594
Metastases to lung 80.43 21.55 44 12073 10652 46663293
Alanine aminotransferase increased 74.84 21.55 103 12014 88348 46585597
Metastatic renal cell carcinoma 72.32 21.55 21 12096 942 46673003
Palmar-plantar erythrodysaesthesia syndrome 65.30 21.55 49 12068 20402 46653543
Hypothyroidism 60.27 21.55 56 12061 31282 46642663
Blood bilirubin increased 59.87 21.55 58 12059 34126 46639819
Aspartate aminotransferase increased 59.68 21.55 87 12030 78613 46595332
Vomiting 56.97 21.55 250 11867 452544 46221401
Posterior reversible encephalopathy syndrome 54.49 21.55 39 12078 15102 46658843
Hepatic enzyme increased 52.94 21.55 84 12033 81703 46592242
Renal cancer metastatic 51.41 21.55 13 12104 343 46673602
Jaundice 50.62 21.55 49 12068 28796 46645149
Drug hypersensitivity 48.38 21.55 4 12113 243821 46430124
Uterine leiomyosarcoma 48.33 21.55 8 12109 19 46673926
Metastases to pancreas 47.70 21.55 11 12106 194 46673751
Dysgeusia 46.62 21.55 55 12062 40436 46633509
Hepatotoxicity 44.85 21.55 43 12074 24966 46648979
Metastases to liver 43.57 21.55 38 12079 19547 46654398
Blood pressure increased 43.19 21.55 99 12018 126567 46547378
Leiomyosarcoma metastatic 41.89 21.55 7 12110 18 46673927
Metastases to peritoneum 41.48 21.55 18 12099 2630 46671315
Transaminases increased 41.07 21.55 43 12074 27718 46646227
Hypertensive crisis 39.89 21.55 31 12086 13584 46660361
Desmoplastic small round cell tumour 39.45 21.55 9 12108 151 46673794
Renal cancer 38.38 21.55 18 12099 3150 46670795
Metastases to central nervous system 38.31 21.55 28 12089 11193 46662752
Leiomyosarcoma 37.32 21.55 9 12108 194 46673751
Proteinuria 36.58 21.55 32 12085 16521 46657424
Pneumothorax 35.84 21.55 30 12087 14599 46659346
Angiosarcoma 35.35 21.55 9 12108 244 46673701
Neurofibrosarcoma 34.54 21.55 8 12109 144 46673801
Left ventricular dysfunction 33.68 21.55 25 12092 10230 46663715
Condition aggravated 31.70 21.55 12 12105 245040 46428905
Sarcoma 30.44 21.55 9 12108 430 46673515
Ageusia 29.08 21.55 24 12093 11448 46662497
Dehydration 27.11 21.55 97 12020 159443 46514502
Ejection fraction decreased 26.92 21.55 28 12089 17909 46656036
Fall 26.32 21.55 28 12089 329069 46344876
Neoplasm progression 25.48 21.55 33 12084 26650 46647295
Hyperthyroidism 24.60 21.55 22 12095 11689 46662256
Asthenia 23.85 21.55 150 11967 310925 46363020
Joint swelling 23.43 21.55 7 12110 166066 46507879
Skin hypopigmentation 23.31 21.55 7 12110 353 46673592
Pleural effusion 23.09 21.55 60 12057 82892 46591053
Ascites 22.85 21.55 37 12080 36547 46637398
Toxicity to various agents 21.89 21.55 14 12103 211752 46462193
Renal cancer recurrent 21.77 21.55 3 12114 0 46673945
Stomatitis 21.74 21.55 52 12065 68245 46605700
Cell death 21.71 21.55 11 12106 2277 46671668

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hair colour changes 758.19 18.27 178 17711 1387 29933202
Malignant neoplasm progression 669.28 18.27 457 17432 71830 29862759
Diarrhoea 516.46 18.27 797 17092 333306 29601283
Death 280.41 18.27 639 17250 356644 29577945
Renal cell carcinoma 240.57 18.27 100 17789 5666 29928923
Decreased appetite 231.13 18.27 359 17530 149551 29785038
Fatigue 218.97 18.27 544 17345 320129 29614460
Metastases to lung 192.23 18.27 94 17795 7801 29926788
Renal cancer 171.66 18.27 71 17818 3969 29930620
Disease progression 167.92 18.27 222 17667 79652 29854937
Nausea 164.87 18.27 467 17422 296490 29638099
Hypertension 164.00 18.27 274 17615 121080 29813509
Palmar-plantar erythrodysaesthesia syndrome 144.01 18.27 97 17792 14773 29919816
Metastatic renal cell carcinoma 134.35 18.27 52 17837 2440 29932149
Dysgeusia 119.63 18.27 107 17782 24694 29909895
Soft tissue sarcoma 95.26 18.27 19 17870 59 29934530
Renal cancer metastatic 87.49 18.27 26 17863 535 29934054
Hypothyroidism 75.00 18.27 66 17823 14897 29919692
Metastases to bone 70.38 18.27 53 17836 9605 29924984
Hepatic enzyme increased 70.06 18.27 93 17796 33401 29901188
Metastases to central nervous system 66.89 18.27 46 17843 7238 29927351
Blood pressure increased 62.78 18.27 135 17754 71793 29862796
Product use in unapproved indication 60.55 18.27 135 17754 73558 29861031
Pneumothorax 57.43 18.27 59 17830 16134 29918455
Proteinuria 55.78 18.27 58 17831 16087 29918502
Weight decreased 53.95 18.27 205 17684 150716 29783873
Vomiting 50.80 18.27 262 17627 219556 29715033
Ageusia 49.95 18.27 42 17847 8911 29925678
Jaundice 48.63 18.27 77 17812 32409 29902180
Neoplasm progression 47.17 18.27 56 17833 17967 29916622
Alanine aminotransferase increased 46.97 18.27 123 17766 74153 29860436
Metastases to liver 46.84 18.27 46 17843 11919 29922670
Blood thyroid stimulating hormone increased 46.55 18.27 26 17863 2830 29931759
Therapy cessation 46.33 18.27 51 17838 15086 29919503
Nephrotic syndrome 44.09 18.27 35 17854 6850 29927739
Off label use 43.52 18.27 51 17838 249239 29685350
Hepatic function abnormal 42.78 18.27 84 17805 41861 29892728
Synovial sarcoma metastatic 42.61 18.27 8 17881 16 29934573
Blood bilirubin increased 41.85 18.27 77 17812 36559 29898030
Metastases to lymph nodes 41.02 18.27 27 17862 3950 29930639
Tumour pain 40.53 18.27 17 17872 983 29933606
Hepatotoxicity 40.44 18.27 52 17837 18093 29916496
Hypotension 39.51 18.27 37 17852 200528 29734061
Malignant connective tissue neoplasm 38.54 18.27 6 17883 0 29934589
Toxicity to various agents 36.92 18.27 31 17858 177152 29757437
Clear cell renal cell carcinoma 34.99 18.27 15 17874 916 29933673
Liver function test increased 34.68 18.27 38 17851 11178 29923411
Abdominal pain upper 33.97 18.27 98 17791 62453 29872136
Skin depigmentation 32.65 18.27 11 17878 344 29934245
Pulmonary necrosis 32.50 18.27 11 17878 349 29934240
Taste disorder 31.98 18.27 22 17867 3461 29931128
Fall 30.85 18.27 38 17851 181834 29752755
Condition aggravated 30.11 18.27 23 17866 137843 29796746
Drug interaction 29.55 18.27 46 17843 199522 29735067
Stomatitis 28.04 18.27 66 17823 37213 29897376
Neoplasm recurrence 27.74 18.27 16 17873 1851 29932738
Overdose 27.70 18.27 8 17881 84329 29850260
Asthenia 26.58 18.27 224 17665 221066 29713523
Aspartate aminotransferase increased 25.84 18.27 90 17799 63332 29871257
Retroperitoneal cancer 25.70 18.27 4 17885 0 29934589
Angiosarcoma 23.43 18.27 8 17881 261 29934328
Sepsis 23.36 18.27 32 17857 146363 29788226
Abdominal discomfort 23.23 18.27 73 17816 48718 29885871
Angiosarcoma metastatic 23.18 18.27 5 17884 25 29934564
Dysphonia 22.99 18.27 41 17848 18991 29915598
Faeces pale 22.86 18.27 13 17876 1464 29933125
Metastases to adrenals 22.54 18.27 11 17878 907 29933682
Blood alkaline phosphatase increased 21.80 18.27 54 17835 31433 29903156
Cardio-respiratory arrest 21.67 18.27 4 17885 57302 29877287
Drug hypersensitivity 21.59 18.27 7 17882 68512 29866077
Cardiac failure congestive 21.23 18.27 12 17877 84395 29850194
Metastases to pleura 20.98 18.27 8 17881 360 29934229
Pulmonary mass 20.93 18.27 29 17860 10833 29923756
General physical health deterioration 20.85 18.27 116 17773 99828 29834761
Metastases to spine 20.11 18.27 14 17875 2244 29932345
Mucosal inflammation 19.76 18.27 51 17838 30443 29904146
Metastases to kidney 19.66 18.27 7 17882 259 29934330
Liver disorder 19.56 18.27 50 17839 29672 29904917
Hyperthyroidism 19.29 18.27 24 17865 8074 29926515
Glossodynia 19.23 18.27 16 17873 3345 29931244
Somnolence 18.84 18.27 18 17871 96745 29837844
Skin hypopigmentation 18.66 18.27 7 17882 301 29934288
Synovial sarcoma 18.38 18.27 4 17885 21 29934568
Intestinal perforation 18.33 18.27 24 17865 8495 29926094
Polycythaemia 18.33 18.27 12 17877 1740 29932849

Pharmacologic Action:

SourceCodeDescription
ATC L01EX03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:65207 vegfr inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Sarcoma of soft tissue indication 424952003
Renal cell carcinoma indication 702391001 DOID:4450
Hypocalcemia contraindication 5291005
Acute hemorrhage contraindication 8573003
Hyperbilirubinemia contraindication 14783006 DOID:2741
Myocardial infarction contraindication 22298006 DOID:5844
Proteinuria contraindication 29738008 DOID:576
Torsades de pointes contraindication 31722008
Gastrointestinal fistula contraindication 37831005
Hypertensive disorder contraindication 38341003 DOID:10763
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Diarrhea contraindication 62315008
Gastrointestinal hemorrhage contraindication 74474003
Pancreatitis contraindication 75694006 DOID:4989
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Angina pectoris contraindication 194828000
Drug-induced hepatitis contraindication 235876009
Impaired wound healing contraindication 271618001
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Surgical procedure contraindication 387713003
Cardiovascular event risk contraindication 395112001
UGT1A1*28 polymorphism contraindication 430235005
Congenital long QT syndrome contraindication 442917000
Hypertensive urgency contraindication 443482000
Acute Thromboembolic Stroke contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.3 acidic
pKa2 5.69 Basic
pKa3 1.23 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Kd 7.85 CHEMBL CHEMBL
Platelet-derived growth factor receptor alpha Kinase INHIBITOR Kd 8.31 CHEMBL CHEMBL
Tyrosine-protein kinase Lck Kinase INHIBITOR Kd 5.92 CHEMBL CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase INHIBITOR Kd 8.10 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Kd 7.57 CHEMBL CHEMBL
Fibroblast growth factor receptor 3 Kinase INHIBITOR Kd 6.21 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 8.70 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 8.74 CHEMBL CHEMBL
Fibroblast growth factor receptor 1 Kinase INHIBITOR Kd 6 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR Kd 7.85 CHEMBL CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase INHIBITOR CHEMBL CHEMBL
MAP/microtubule affinity-regulating kinase 3 Kinase Kd 5.40 CHEMBL
Aurora kinase A Kinase Kd 5.15 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.32 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 5.33 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 6.05 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 5.72 CHEMBL
Cyclin-dependent kinase 11B Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.12 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 6.37 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.80 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.12 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 6.82 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.08 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 6.44 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 6.54 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 5.54 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.16 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 5.30 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.62 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.24 CHEMBL
Aurora kinase C Kinase Kd 6.12 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 6.68 CHEMBL
Mitogen-activated protein kinase kinase kinase 10 Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.52 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 6.55 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 6.33 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 5.06 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 6.13 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 6.51 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6.62 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 6 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.47 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 5.23 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 5.64 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 5.74 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 6.01 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.05 CHEMBL
LIM domain kinase 1 Kinase Kd 6.14 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 5.80 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase Nek5 Kinase Kd 5.14 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 6.10 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 6.54 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.52 CHEMBL
Activin receptor type-2B Kinase Kd 5.62 CHEMBL
Cyclin-G-associated kinase Kinase Kd 6.70 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.48 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma Kinase Kd 5.72 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase Kd 6.04 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 7.09 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 5.14 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 7.35 CHEMBL
Tyrosine-protein kinase Srms Kinase Kd 5.60 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.54 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.57 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.01 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 6.15 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.52 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.57 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 7.24 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.66 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 5.85 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.70 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 6.54 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 5.17 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 6.03 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 6.23 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 5.59 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 6 Kinase Kd 5.39 CHEMBL
LIM domain kinase 2 Kinase Kd 6.41 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 5.66 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 6.59 CHEMBL
Cyclin-dependent kinase 11A Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase RIO2 Kinase Kd 6.21 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 5.36 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 5.66 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 5.48 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.01 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 5.59 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.72 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 6.42 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 6.13 CHEMBL
Phosphatidylinositol 4-kinase beta Kinase Kd 6.02 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.55 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 5.68 CHEMBL
Fibroblast growth factor receptor 4 Kinase Kd 5.55 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.70 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 6.24 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 5.77 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.43 CHEMBL

External reference:

IDSource
4029464 VUID
N0000180309 NUI
D05380 KEGG_DRUG
635702-64-6 SECONDARY_CAS_RN
4029464 VANDF
C1872226 UMLSCUI
CHEBI:71217 CHEBI
CHEMBL1201733 ChEMBL_ID
CHEMBL477772 ChEMBL_ID
DB06589 DRUGBANK_ID
C516667 MESH_SUPPLEMENTAL_RECORD_UI
5698 IUPHAR_LIGAND_ID
8681 INN_ID
7RN5DR86CK UNII
10113978 PUBCHEM_CID
714438 RXNORM
168598 MMSL
26797 MMSL
d07499 MMSL
013302 NDDF
013303 NDDF
443763005 SNOMEDCT_US
443764004 SNOMEDCT_US
735169009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VOTRIENT HUMAN PRESCRIPTION DRUG LABEL 1 0078-0670 TABLET, FILM COATED 200 mg ORAL NDA 34 sections